scholarly journals Early Outcome of Treatment of Chronic Mesenteric Ischemia

2015 ◽  
Vol 81 (11) ◽  
pp. 1149-1156 ◽  
Author(s):  
Zhobin Moghadamyeghaneh ◽  
Joseph C. Carmichael ◽  
Steven D. Mills ◽  
Matthew O. Dolich ◽  
Alessio Pigazzi ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Odds Ratio ◽  
Open Surgery ◽  
Mesenteric Ischemia ◽  
Chronic Mesenteric Ischemia ◽  
Limited Data ◽  
Long Term Outcomes ◽  
Mortality And Morbidity ◽  
Vascular Insufficiency

There are limited data regarding long-term outcomes of chronic mesenteric ischemia (CMI) of the intestine. We sought to identify treatment outcomes of CMI. The NIS database was used to identify patients admitted for the diagnosis of CMI between 2002 and 2012. Multivariate analysis using logistic regression was performed to quantify outcomes of CMI. A total of 160,889 patients were admitted for chronic vascular insufficiency of intestine; of which 7,906 patients underwent surgical/endovascular treatment for CMI. Among patients who underwent surgery 62 per cent had endovascular treatment and 38 per cent had open vascular treatment. Need of open surgery (adjusted odds ratio (AOR): 5.13, P < 0.01) and age ≥70 years (AOR: 3.41, P < 0.01) had strong associations with mortality of patients. Open vascular treatment has higher mortality (AOR: 5.07, P < 0.01) and morbidity (AOR: 2.14, P < 0.01). However, endovascular treatment had higher risk of postoperative wound hematoma (AOR: 2.81, P < 0.01). Most patients admitted for CMI are treated with endovascular treatment. Endovascular treatment has the advantage of lower mortality and morbidity. Need to open surgery and age ≥70 years have strong associations with mortality of patients.

scholarly journals Role for Endovascular Therapy in Chronic Mesenteric Ischemia

2009 ◽  
Vol 23 (5) ◽  
pp. 365-373 ◽  
Author(s):  
Romaric Loffroy ◽  
Eric Steinmetz ◽  
Boris Guiu ◽  
Valérie Molin ◽  
Benjamin Kretz ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Mesenteric Ischemia ◽  
Rare Condition ◽  
Primary Treatment ◽  
Transluminal Angioplasty ◽  
Mesenteric Arteries ◽  
Long Term Results ◽  
Chronic Mesenteric Ischemia ◽  
Interventional Devices

Chronic mesenteric ischemia is a rare condition that is caused by stenosis or occlusion of the mesenteric arteries and usually manifests as abdominal pain. While surgical revascularization has been the standard treatment for symptomatic patients, recent advances in interventional devices and techniques have made endovascular treatment feasible and effective. Percutaneous transluminal angioplasty with stent placement is now recognized as a minimally invasive means of obtaining good long-term results with an acceptable recurrence rate; consequently, the technique is suggested for the primary treatment of chronic mesenteric ischemia. The present article discusses the indications and principles of endovascular treatment, and reviews the literature, with emphasis on short- and long-term outcomes, particularly morbidity and mortality rates.

Factors predicting long-term outcomes of percutaneous angioplasty and stenting of the superior mesenteric artery for chronic mesenteric ischemia

VASA ◽  
2021 ◽  
Author(s):  
Joris Awouters ◽  
Thomas Jardinet ◽  
Martin Hiele ◽  
Annouschka Laenen ◽  
Steven Dymarkowski ◽  
...  
Keyword(s):  
Mesenteric Artery ◽  
Mesenteric Ischemia ◽  
Chronic Mesenteric Ischemia ◽  
Percutaneous Angioplasty ◽  
Long Term Outcomes ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Angioplasty And Stenting

Summary: Background: To analyse the long-term outcomes of percutaneous angioplasty and stenting of the superior mesenteric artery (SMA) in the treatment of chronic mesenteric ischemia (CMI), and to assess predictive factors for a better clinical outcome. Patients and methods: Retrospective analysis of 76 consecutive patients, treated percutaneously for CMI between January 1999 and January 2018 and followed up until the end of 2018. Patients’ pre-, peri- and post-interventional clinical and radiological data were gathered from the institutional electronic medical records. The Kaplan Meier method with log rank test or the Cox model were used to analyse overall survival; the cumulative incidence function with Pepe and Mori test or the Fine and Grey model were used to analyse relapse-free survival, considering death as a competing event. Results: Seventy-six consecutive patients with a mean age of 72 years were included in the study. Catheter-angiography revealed an ostial or non-ostial >90% stenosis in n=23 (29.7%) and n=53 (69.7%) of included patients, respectively. Immediate clinical success was achieved in n=68 (89.5%), and procedural complications were observed in n=13 (17.1%) patients. Long-term follow-up revealed relapse of symptoms in n=21 (28.8%) patients, and overall survival estimates are 81.8%, 57.0% and 28.2% after two, five and ten years of follow-up, respectively. A trend towards longer relapse-free survival was found in the circumferential stenosis group (78.2% at five years) compared with the non-circumferential stenosis group (55.5%) (P=0.063). Conclusions: Angioplasty and stenting of the SMA for CMI is relatively safe and effective despite a substantial number of patients experiencing clinical relapse over time. Patients with focal, circumferential stenosis might have longer relapse-free survival than patients with non-circumferential stenosis.

scholarly journals Mid-term outcomes of endovascular treatment for symptomatic chronic mesenteric ischemia

2011 ◽  
Vol 1 (1) ◽  
pp. 2 ◽  
Author(s):  
Eva Schönefeld ◽  
Susanne Szesny ◽  
Konstantinos P. Donas ◽  
Georgios A. Pitoulias ◽  
Giovanni Torsello
Keyword(s):  
Endovascular Treatment ◽  
Mesenteric Ischemia ◽  
Primary Patency ◽  
Mesenteric Arteries ◽  
Primary Study ◽  
Symptom Improvement ◽  
Initial Symptom ◽  
Secondary Patency ◽  
Chronic Mesenteric Ischemia

The authors would present the mid-term outcomes with the use of stent-supported angioplasty in the treatment of symptomatic chronic mesenteric ischemia (CMI). The present study is a retrospective analysis of 36 patients undergoing endovascular treatment of symptomatic CMI, between November 2000 and September 2009. Primary study endpoints were defined as primary patency, periprocedural and midterm mortality and complications, and symptom improvement after intervention. Forty-one mesenteric arteries (77.3% stenotic and 22.7% occluded vessels) were treated in 36 patients with 42 stents. In 30 patients (83.3%) one visceral artery and in 6 cases (16.7%) two visceral arteries were treated. Overall mortality was 16.7% (n=6) after a 60-month follow-up (mean follow-up period 30.1 months). Two early (&lt;30-day) deaths were caused by visceral ischemia (n=2: 5.5%). Late death was procedure-related in one patient with re-occlusion of the superior mesenteric artery after 12 months. The other 3 patients died from non procedure-related causes; e.g. twice myocardial infarction. Initial symptom relief was observed in 29 patients (80.5%); 7 patients reported no change. Primary patency was 83.3% after 5 years and secondary patency was 90.5% (38 out of 42 stents) among all patients. Two conversions to open surgery were documented. First-line endovascular approach of CMI is a reasonable strategy. Close follow-up is mandatory due to symptom recurrence and restenosis.

scholarly journals Open Replacement of the Thoracoabdominal Aorta: Short- and Long-term Outcomes at a Single Institution

2018 ◽  
Vol 27 (02) ◽  
pp. 114-120
Author(s):  
Davide Carino ◽  
Young Erben ◽  
Mohammad Zafar ◽  
Mrinal Singh ◽  
Adam Brownstein ◽  
...  
Keyword(s):  
Aortic Dissection ◽  
Open Surgery ◽  
Elective Surgery ◽  
Aortic Diseases ◽  
Long Term Outcomes ◽  
Thoracoabdominal Aorta ◽  
Primary Endpoints ◽  
Short And Long Term ◽  
Optimal Approach

Background Despite much progress in the surgical and endovascular treatment of thoracoabdominal aortic diseases (TAADs), there is no consensus regarding the optimal approach to minimize operative mortality and end-organ dysfunction. We report our experience in the past 16 years treating TAAD by open surgery. Methods A retrospective review of all TAAD patients who underwent an open repair since January 2000 was performed. The primary endpoints included early morbidity and mortality, and the secondary endpoints were overall death and rate of aortic reintervention. Results There were 112 patients treated by open surgery for TAAD. Mean age was 66 ± 10 years and 61 (54%) were male. Seventy-seven (69%) patients had aneurysmal degeneration without aortic dissection and the remaining 35 (31%) had a concomitant aortic dissection. There were 12 deaths (10.7%) and they were equally distributed between the aneurysm and dissection groups (p = 0.8). The mortality for elective surgery was 3.2% (2/61). The rate of permanent paraplegia and stroke were each 2.6% (3/112). The rate of cerebrovascular accident was significantly higher in the dissection group (8.5% vs. 1.2%, p = 0.05). The survival at 1, 5, and 10 years was 80.6, 56.1, and 32.7%, respectively. Conclusion Our data confirm that open replacement of the thoracoabdominal aorta can be performed in expert centers quite safely. Different aortic pathologies (degenerative aneurysm vs. dissection) do not influence the short- and long-term outcomes. Open surgery should still be considered the standard in the management of TAAD.

scholarly journals Excellent long-term outcomes of endovascular treatment in budd–chiari syndrome with hepatic veins involvement

Medicine ◽  
2018 ◽  
Vol 97 (43) ◽  
pp. e12944 ◽  
Author(s):  
Yonghua Bi ◽  
Hongmei Chen ◽  
Pengxu Ding ◽  
Pengli Zhou ◽  
Xinwei Han ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Hepatic Veins ◽  
Budd Chiari Syndrome ◽  
Long Term Outcomes ◽  
Chiari Syndrome
Sign in / Sign up

Export Citation Format

Share Document